Taysha Gene Therapies Announces Virtual Investor Events in January 2022 to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High-Dose Cohort and Long-Term Clinical Data for TSHA-120 in Axonal Neuropathy giant
DALLAS – (COMMERCIAL THREAD) – Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centered, pivotal stage gene therapy company focused on the development and commercialization of AAV-based gene therapies for the treatment of disease monogenic central nervous system (CNS) in rare and large patient populations, today announced its intention to provide clinical data updates, including its intention to host two virtual conference calls from investors and webcasts in January 2022 to discuss preliminary clinical data for TSHA-101 in gangliosidosis GM2 and the high-dose cohort and long-term clinical data for TSHA-120 in giant axonal neuropathy (GAN) from the respective phase trials 1/2 in progress.
Taysha will host two separate conference calls and webcasts in January 2022 with the following topics on the agenda:
TSHA-101 in GM2 gangliosidosis
- Preliminary clinical safety data and Hex A enzyme activity in serum and cerebrospinal fluid for TSHA-101
- Current status of the program and planned next steps
TSHA-120 in giant axonal neuropathy (GAN)
- Clinical Safety and Efficacy Data for TSHA-120 in the Highest Dose Cohort of 3.5×1014 total vg
- Update on long-term clinical safety and efficacy data for 1.2×1014 and 1.8×1014 TSHA-120 total vg doses
- Overview of the global regulatory and marketing strategy
Links to webcasts and connection instructions for conference calls will be available through the “Events and mediaFrom the Taysha Company website. Archived versions of events will be available on the website for 60 days.
About Taysha gene therapies
Taysha Gene Therapies (Nasdaq: TSHA) is dedicated to eradicating monogenic CNS disease. By focusing singularly on the development of curative drugs, we aim to rapidly translate our treatments from the laboratory to the bedside. We have combined our team’s proven track record in gene therapy drug development and commercialization with UT’s world-class Southwestern Gene Therapy program to create an extensive AAV gene therapy pipeline focused on rare and very expensive indications. Together, we are leveraging our fully integrated platform, an engine for potential new treatments, with the goal of dramatically improving the lives of patients. More information is available at www.tayshagtx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “expects”, “intends”, “plans” “And” future “or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the potential of our product candidates, including TSHA-120, to positively impact quality of life and to alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates. , the eligibility of TSHA-120 for expedited approval in the United States and Europe, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if they are approved, these product candidates will be successfully distributed and marketed, and the potential market opportunity for these product candidates. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Therefore, these forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. The risks to our business are described in detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report. on Form 10-Q for the quarter ended September 30, 2021, both available on the SEC’s website at www.sec.gov. Additional information will be made available in other documents that we file from time to time with the SEC. These risks may be magnified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update such statements, except as required by law.